title: Role of bile acid sequestrants in the treatment of type 2 diabetes.
authors.affiliation: Metabolic Institute of America, Tarzana, California, USA. yhandelsman@pacbell.net
authors.forename: Yehuda
authors.initials: Y
authors.lastname: Handelsman
mesh_terms: D000499:Allylamine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D001647:Bile Acids and Salts / Q000009:adverse effects / Q000627:therapeutic use; D002792:Cholestyramine Resin / Q000009:adverse effects / Q000627:therapeutic use; D000069472:Colesevelam Hydrochloride; D003084:Colestipol / Q000009:adverse effects / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004811:Epichlorohydrin / Q000009:adverse effects / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use; D012117:Resins, Synthetic / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D001647:Bile Acids and Salts; D000960:Hypolipidemic Agents; D007093:Imidazoles; D012117:Resins, Synthetic; C417427:colestimide; D004811:Epichlorohydrin; D002792:Cholestyramine Resin; D000499:Allylamine; D003084:Colestipol; D000069472:Colesevelam Hydrochloride; C106574:cholebine